Reata Pharmaceuticals IncReata Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The report of Reata Pharmaceuticals Inc employs information from across the web and also from public filings by Reata Pharmaceuticals Inc. Jump to the end of the webpage for potential risks for Reata Pharmaceuticals Inc based on industry, location and marketcap. The article includes a questions and answers table on Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 0.0, social score of 2.3 and governance score of 1.3.

SDG Transparency Score for Reata Pharmaceuticals Inc 

1.2

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Reata Pharmaceuticals Inc 
0.0

Environmental

2.3

Social

1.3

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
.........
1755TRACON Pharmaceuticals Inc
1.3
Low
1755Trimurthi Ltd
1.3
Low
1779Reata Pharmaceuticals Inc
1.2
Low
1779Cell Biotech Co Ltd
1.2
Low
1779Aurisco Pharmaceutical Co Ltd
1.2
Low
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Reata Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc offer flexible work?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose water use targets?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Reata Pharmaceuticals Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Reata Pharmaceuticals Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Reata Pharmaceuticals Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose its waste policy?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose energy use targets?

LockedSign up for free to unlock

Does Reata Pharmaceuticals Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Reata Pharmaceuticals Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Reata Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Sorry!

Failed to process!